We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

BVXP Bioventix Plc

0.00 (0.0%)
30 Nov 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Bioventix Plc LSE:BVXP London Ordinary Share GB00B4QVDF07 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 3,900.00 3,850.00 3,950.00 3,900.00 3,900.00 3,900.00 3,502 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 12.82M 8.37M 1.6071 24.27 203.16M

Bioventix Share Discussion Threads

Showing 1326 to 1348 of 1550 messages
Chat Pages: 62  61  60  59  58  57  56  55  54  53  52  51  Older
The VTLi POC machine uses a mouse monoclonal antibody. I believe the VTLi machine was acquired from Phillips a couple years back which might explain why it doesn't use the Bioventix antibody.
Gorrit - cut the laboratory out of the loop.

"Point-of-Care Cardiac Troponin Testing
Central laboratories are not always on-site, nor available for use 24 hours a day, seven days a week. Point-of-care (POC) testing is a care model that moves the assay to the patient and is now available to measure cTn levels. POC cTn tests offer a significantly shorter turnaround time for biomarker detection, typically providing results within 10 to 20 minutes.4 POC cTn testing has been used with the goal to expedite patient care both in hospital emergency departments and in various settings where central laboratory testing is not available, including use by paramedics aboard a land or air ambulance, and by health personnel in rural health care centres or remote locations. Use of POC cTn testing could potentially speed up therapeutic decisions and decisions around patient transfers, hospital admissions, and discharge for patients presenting with ACS. Theoretically, the result could be less congested emergency departments and fewer transfers of patients to larger hospitals for further assessment. Improved patient flow may result in cost reductions from fewer unnecessary hospital admissions and laboratory costs.9

POC cTn testing is more expensive than laboratory testing, with one manufacturer citing $12.50 per test. However, a cost-per-test approach is not an informative cost comparison with laboratory testing; rather, the question is how POC testing compares with laboratory testing when examining factors beyond the costs of reagents to include the costs of running the POC program (for example, training, quality assurance and quality control, maintenance, data management) and savings from avoiding the costs of patient transfers and hospital admissions.

There are several POC troponin devices available in Canada produced by various manufacturers that test for one or both types of cTn (cTnI and cTnT). A list of POC troponin devices approved in Canada is provided in Appendix 1.

Go to:
1.4. Decision-Making About Point-of-Care Troponin Testing
It is unknown whether health outcomes can be improved and if cost savings can be realized with POC cTn testing in various Canadian health care settings (such as hospitals with a central laboratory, community hospitals, remote locations, hospitals without a central laboratory, remote nursing stations, medical clinics, long-term care settings, and emergency medical services). To answer these questions, a review of the clinical and economic evidence on POC troponin testing is needed to inform decisions about its acquisition and use."

"Good spot. Unless it is much more specific than current assays, not sure about the clinical need for another troponin assay."
Particularly as BVXP's is approved and the cost/time for a new approval is very high.
There must be something that we don't know. Haven't been able to find anything else.

SP stagnation is unsurprising. News in Oct. and they don't do intermediate rns.


Good spot. Unless it is much more specific than current assays, not sure about the clinical need for another troponin assay.

Any thoughts on the share price drop of late? Just got the death cross (20d under 50d MA).

I thought that NICE recommending Vitamin D for all would reduce assay measurement, which the company has forecast. However, Vitamin D revenues have continued to grow to date.

Long article behind paywall

Siemens Healthineers Rolling Out High-Sensitivity POC Troponin Assay in Europe

"...Siemens Healthineers recently began shipping its first Atellica VTLi Patient-Side Immunoassay Analyzers with a test for troponin I, a protein biomarker of acute myocardial infarction, to hospital emergency departments in Europe."

"...By establishing a footprint in Europe and other regions that accept CE marking, the firm gains an early-mover advantage in the testing market for cardiac conditions at the point of care" and "...the first p-o-c high-sensitivity cardiac troponin I test with results comparable to laboratory performance using just a fingerstick sample" Christoph Pedain, head of point-of-care diagnostics at Siemens Healthineers said

Also conducting a clinical validation study to prepare for a submission for FDA clearance though timeline for the submission is uncertain.

I suspect its unlikely as the 3 monoclonal antibodies on the UK market (Erenumab, Fremanezumab and Galcanezumab) and the one that is under review by NICE (Eptinezumab) are all humanized monoclonals rather than sheep monoclonals.
Just read an interesting article on King’s College London’s work on a possible cure for migraine using monoclonal antibodies. No mention of who supplies the antibodies but may have to ask BVXP if they are involved. Apparently one billion people around the World suffer from migraines so this could be huge for whoever manufactures the antibodies.

Blog posting profiling BVXP
Still nothing via my AJ Bell account.

The same thing happened with ABDP a few weeks ago when I got mine two working days after everyone with holdings elsewhere.

Not impressed.

Yes - iWeb and ii
Div received in HL a/c
alter ego
YUP. Charles Stanley always on time.
Yes - through ii this am.

Anyone received their dividend yet ?
I think Bioventix own 10%

Intuitive Investments Group plc

Investment in CardiNor AS

Intuitive Investments Group plc (AIM: IIG) ("IIG" or the "Company"), a closed-end investment company focussed on the life sciences sector, announces an investment of £125,000 to acquire ordinary shares in CardiNor AS ("CardiNor"), representing a 1.8 per cent. interest in CardiNor's enlarged share capital.

CardiNor is a Norwegian biotech company established in June 2015 to commercialise the development of secretoneurin ("SN"), an important new biomarker for cardiovascular disease ("CVD"). SN is the only biomarker shown to be associated with biological processes linked to cardiomyocyte handling. This unique biological function explains why SN presents as an independent and strong predictor of mortality in all major patient cohorts, including ventricular arrhythmia, acute heart failure, acute respiratory failure patients with CVD and severe sepsis. CardiNor has completed development of a research assay based on immunoassay technology to measure SN in blood and the assay is under further clinical development, including to obtain a CE mark. More information can be found at: hxxps:// .

In the year ended 31 December 2020 , per CardiNor's unaudited management accounts, it achieved a loss after tax of approximately £141,000 and, as at 31 December 2020, had net assets of approximately £500,000, assuming an exchange rate of 11.87NOK/GBP.

Anything revealing at Mello on Biovenrix? Thanks N
Thank you for the explanation

Piedro, yes I initially thought there must be a mistake or exceptional adjustments made, but then recalled the last half-year results to Dec'19 were restated due to a sales rebate not being entered into the accounting system, a pretty silly mistake really and not clear how that could have happened. This is from the correction note on 31 March 2020:

Correction - Unaudited Interim Results for the six months ended 31 December 2019

The Company has become aware that due to an administration error a sales rebate of $219k (£167k) was not entered into the accounting system. Consequently revenues for the six month period were £5.1m not the £5.3m as reported on 30 March 2020. Pre tax profits were £4.1m as opposed to £4.3m as previously stated. The cash figure and interim dividend remain unchanged.

Please can someone explain me the following ...

In these Interim Results
TURNOVER for the 6 months ended 31/12/2019 = £5,098,588
whereas from the previous Interim Results
TURNOVER for the 6 months ended 31/12/2019 = £5,265,270



Wildshot - what is the point of incurring hedging cost and time on fx?

Why not just take the gains and losses as they arise instead of delaying them - which is all that hedging effectively does, at a cost.

Hi Boros10, thanks for doing the session. If possible could you cover the forex management and whether they are likely to hedge in future to reduce the impact on margins by exchange gains/losses?
Leon - I second nigeldough1 - would like to understand more about the pollution project - sounds a bit different from the usual type of blood test.
Investor's Champion comment:

As always, Bioventix swiftly converted profits into cash, with the operating cash inflow £3.3m and free cash inflow £3.2m, leaving period end cash of £5.8m well able to support a 20% increase in the first interim dividend to 43p per share.

Chat Pages: 62  61  60  59  58  57  56  55  54  53  52  51  Older

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |